 | GRAd-COV2 is a COVID-19 vaccine candidate developed by ReiThera Srl and Lazzaro Spallanzani National Institute for Infectious Diseases. It is based on... 4 KB (202 words) - 14:35, 24 August 2023 |
 | May 2021. "ReiThera: GRAd-COV2 – COVID19 Vaccine Tracker". covid19.trackvaccines.org. Retrieved 8 May 2021. "ReiThera GRAd-COV2 vaccine". clinicaltrialsregister... 159 KB (11,635 words) - 14:00, 13 February 2024 |
biotech company ReiThera to test a COVID-19 vaccine candidate called GRAd-COV2, which is based on a modified gorilla adenovirus vector. "Nurse in Italy... 2 KB (222 words) - 12:29, 17 April 2023 |
| October 2021. "GRAd-COV2 Vaccine Against COVID-19". ClinicalTrials.gov. 27 August 2020. NCT04528641. "ReiThera Announces its GRAd-COV2 COVID-19 Vaccine... 98 KB (20,593 words) - 02:58, 8 March 2024 |
Biotech Viral vector AdCLD-CoV19 BriLife COH04S1 DelNS1-2019-nCoV-RBD-OPT GRAd-COV2 ImmunityBio iNCOVACC INNA-051 NDV-HXP-S Vaxart COVID-19 vaccine Virus-like... 181 KB (23,901 words) - 14:23, 6 January 2024 |
 | Vaccine Type (technology) Phase I Phase II Phase III GRAd-COV2 Viral vector Completed Completed In progress COVID-eVax DNA In progress In progress Not... 45 KB (3,117 words) - 21:35, 24 February 2024 |
| Phase I Phase II Phase III Novavax Subunit Completed Completed Completed GRAd-COV2 Viral vector Completed Completed In progress Patria Viral vector Completed... 13 KB (1,010 words) - 21:47, 21 October 2023 |
 | source and freely available to the public. The DNA vaccine expressed the SARS-CoV2 spike protein once inside human cells to elicit an immune response. She measured... 25 KB (2,005 words) - 23:31, 19 December 2023 |